The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
Suurstoffi 22
P.O. Box 94
CH-6343 Rotkreuz
Telephone +41 41 3690 300
Medical questions or adverse event reports can be directed to Amgen Medical Information.
For product questions or to report an adverse event or safety related issue, or to report a quality issue with a product or device:
Call +1 800-772-6436 (800-77-AMGEN) or +1 805-447-3505
If you are based outside of the US please click here for local contact information.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.